Szajewska Hania, Horvath Andrea, Koletzko Berthold
Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland.
Am J Clin Nutr. 2006 Jun;83(6):1337-44. doi: 10.1093/ajcn/83.6.1337.
It is hypothesized that the intake of long-chain polyunsaturated fatty acids (LC-PUFAs) throughout pregnancy is important to maternal health and fetal and infant development.
The objective was to evaluate systematically the effect of LC-PUFA supplementation of pregnant women's diets on pregnancy outcomes and growth measures at birth.
We searched MEDLINE, EMBASE, CINAHL, and the Cochrane Library through August 2005 and also searched the references in reviewed articles for randomized controlled trials (RCTs) comparing LC-PUFA supplementation with placebo or no supplementation.
Of 6 included RCTs, only 1 was judged to be at low risk of bias. Supplementation with n-3 LC-PUFAs in these 6 RCTs (1278 infants) was associated with a significantly greater length of pregnancy [weighted mean difference (WMD): 1.57 d; 95% CI: 0.35, 2.78 d; findings stable on sensitivity analysis] than in control subjects. We found no evidence that supplementation influenced the percentage of preterm deliveries, the rate of low-birth-weight infants, or the rate of preeclampsia or eclampsia. We found no significant difference in the 6 RCTs (1278 infants) in birth weight (WMD: 54 g; 95% CI: -3.1, 111 g) and no significant difference in 5 RCTs (1262 infants) in birth length (WMD: 0.23 cm; 95% CI: -0.04, 0.5 cm), but, in 4 RCTs (729 infants), there was a significant increase in head circumference (WMD: 0.26 cm; 95% CI: 0.02, 0.49 cm; significance was lost on sensitivity analysis).
n-3 LC-PUFA supplementation during pregnancy may enhance pregnancy duration and head circumference, but the mean effect size is small. The implications of these findings for later growth and development remain to be elucidated.
据推测,孕期摄入长链多不饱和脂肪酸(LC-PUFA)对母体健康以及胎儿和婴儿的发育至关重要。
本研究旨在系统评估孕妇饮食中补充LC-PUFA对妊娠结局和出生时生长指标的影响。
我们检索了截至2005年8月的MEDLINE、EMBASE、CINAHL和Cochrane图书馆,还检索了综述文章中的参考文献,以查找比较补充LC-PUFA与安慰剂或不补充的随机对照试验(RCT)。
在纳入的6项RCT中,只有1项被判定为低偏倚风险。在这6项RCT(1278名婴儿)中,补充n-3 LC-PUFA与妊娠时间显著延长相关[加权平均差(WMD):1.57天;95%置信区间:0.35,2.78天;敏感性分析结果稳定],高于对照组。我们没有发现证据表明补充剂会影响早产百分比、低体重儿发生率或先兆子痫或子痫发生率。在6项RCT(1278名婴儿)中,出生体重没有显著差异(WMD:54克;95%置信区间:-3.1,111克),在5项RCT(1262名婴儿)中,出生身长也没有显著差异(WMD:0.23厘米;95%置信区间:-0.04,0.5厘米),但在4项RCT(729名婴儿)中,头围有显著增加(WMD:0.26厘米;95%置信区间:0.02,0.49厘米;敏感性分析后显著性消失)。
孕期补充n-3 LC-PUFA可能会延长妊娠时间并增加头围,但平均效应量较小。这些发现对后期生长发育的影响仍有待阐明。